Meeting on the Mesa 2026 has ended. This guide stays up as the record of who was there. Next: Meeting on the Mesa 2027, Oct 18–20, 2027 in Phoenix
Gene editing at Meeting on the Mesa 2026
Oct 5–7, 2026 Phoenix, AZ ~1.5k attendees Website
30 organizations at Meeting on the Mesa 2026 present work in gene editing: 21 therapy developers, 8 suppliers and service providers and 1 academic or public organization. Between them they bring 17 presentations to the program. Most represented: Arbor Biotechnologies (1 on the program), ElevateBio (1 on the program), BlueRock Therapeutics (1 on the program). As of Oct 6, 2026.
| Organization | Meeting on the Mesa 2026 Attendance |
|---|---|
Arbor Biotechnologies Cambridge, MA | ◇Silver Sponsor |
Develops gene-editing therapeutics for genetic diseases, including liver and central nervous system conditions and rare disorders. | Spotlight Mon, Oct 5 10:45am Panel Tue, Oct 6 4:15pm |
ElevateBio Waltham, MA | ◆Diamond Sponsor |
Provides gene-editing technologies, discovery services, and cGMP development and manufacturing for advanced therapy companies from early research through commercialization. | Spotlight Mon, Oct 5 11:45am Panel Mon, Oct 5 5:00pm |
BlueRock Therapeutics Cambridge, MA | ◇Silver Sponsor |
Develops engineered cell therapies using pluripotent stem cells and genome editing for neurological, cardiac, and immune diseases. | |
Editas Medicine Cambridge, MA | ◇Silver Sponsor |
Develops CRISPR-based gene-editing medicines for genetic diseases. | Panel Tue, Oct 6 11:15am |
Applied StemCell Milpitas, CA | ◇Silver Sponsor ◇Partnering Sponsor |
Provides CRISPR genome-editing reagents, engineered cell lines, and custom gene-editing services for research and cell therapy development. | Sponsor In the meeting’s sponsor directory, with no session on the public program |
Beam Therapeutics Cambridge, MA | ◇Silver Sponsor |
Develops base-editing medicines that precisely modify genes to treat serious diseases. | Sponsor In the meeting’s sponsor directory, with no session on the public program |
Pluristyx Seattle, WA | |
Provides research and clinical-grade iPSC products, gene-editing technologies, cell differentiation, and development services for cell therapy developers. | Spotlight Mon, Oct 5 3:00pm Panel Mon, Oct 5 5:00pm |
Ascidian Therapeutics Boston, MA | |
Develops RNA exon-editing therapies that restore full-length proteins for retinal, neurological, neuromuscular, renal, and genetically defined diseases. | Spotlight Mon, Oct 5 4:30pm |
Metagenomi Therapeutics Emeryville, CA | |
Develops genome-editing technologies and therapeutic programs for genetic diseases, including engineered editing systems designed for precision and delivery. | Spotlight Mon, Oct 5 11:45am |
NTrans Technologies Leiden, Netherlands | |
Develops nonviral intracellular delivery technology for CRISPR, base and prime editing, including therapies for genetic diseases. | Spotlight Tue, Oct 6 2:00pm |
Precision BioSciences Durham, NC | |
Develops in vivo gene-editing therapies using its ARCUS platform for infectious and rare diseases. | Spotlight Mon, Oct 5 11:30am |
RheumaGen Aurora, CO | |
Develops HLA gene-editing therapies intended to treat rheumatoid arthritis, multiple sclerosis, and other autoimmune diseases. | Spotlight Tue, Oct 6 9:00am |
Scribe Therapeutics Alameda, CA | |
Develops CRISPR-based in vivo genetic medicines, including liver-targeted therapies designed to epigenetically silence disease-related genes. | Spotlight Mon, Oct 5 5:15pm |
Develops Dualase genome-editing therapies delivered by AAV or RNA, initially targeting DNA repeat expansion disorders including inherited ALS. | Spotlight Tue, Oct 6 4:45pm |
Intellia Therapeutics Cambridge, MA | |
Develops CRISPR-based gene-editing therapies for serious diseases, including in vivo and engineered-cell treatment programs. | Panel Tue, Oct 6 9:30am |
Prime Medicine Cambridge, MA | |
Develops gene therapies using Prime Editing to precisely correct disease-causing mutations. | Panel Tue, Oct 6 9:30am |
Cartherics Melbourne, Australia | |
Develops off-the-shelf immune cell therapies using gene-edited cells for ovarian cancer, endometriosis and other diseases. | Attending On the meeting’s published attendee list |
GenScript Nanjing, China | |
Provides gene synthesis, genome-editing, plasmid, viral-vector, cell-therapy and biologics development and manufacturing services, plus research reagents. | Attending On the meeting’s published attendee list |
Helex Cambridge, MA | |
Develops gene-editing medicines using lipid nanoparticles to treat genetic kidney diseases. | Attending On the meeting’s published attendee list |
Find buyers in gene editing
Tell us what you sell and we’ll find the people at organizations working on gene editing most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse Meeting on the Mesa 2026 by
Not affiliated with or endorsed by the Alliance for Regenerative Medicine or the Cell & Gene Meeting on the Mesa. Submit a correction